AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
CEO: Pascal Claude Roland Soriot. Company website
AstraZeneca PLC (AZN) trades at $166.08, down 0.04% on the day, as of Sep 20, 2026 13:06 UTC.
AstraZeneca PLC has a market capitalisation of $257.42B, calculated from the live AZN share price and shares outstanding.
AZN trades at a trailing P/E of 24.94, from earnings per share of $6.66 over the last twelve months.
AstraZeneca PLC generated revenue of $61.37B over the trailing twelve months, which puts the stock at 4.19 times sales.
Yes. AstraZeneca PLC pays a dividend yielding 1.65% on the current share price.
AZN has traded between $146.10 and $212.71 over the past 52 weeks, and the last price is 21.9% below that high.
Yes. AstraZeneca PLC keeps 17.02% of revenue as net income over the trailing twelve months.
Wall Street analysts rate AZN Buy, with an average price target of $186.67, 12.4% above the current price.
AstraZeneca PLC is classified under the Healthcare sector and the Drug Manufacturers - General industry, and is domiciled in GB.
Pascal Claude Roland Soriot is the chief executive of AstraZeneca PLC, which employs 96,100 people.
QFI Terminal shows AZN with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open AZN in Terminal See plans